Current non-invasive diagnostic modalities for liver fibrosis include elastography and circulating markers of liver injury, which lack sensitivity and specificity for the diagnosis of early stages, or they fail to detect small changes in fibrosis progression or regression. We focus on the use of platelet derived growth factor receptor beta (PDGFRβ), a protein known to be associated with hepatic stellate cell activation, as dynamic and sensitive marker of liver fibrosis. In this project we evaluate the diagnostic utility of PDGFRβ and compare it to the current clinical liver fibrosis scoring systems.
Effective start/end date21/12/1820/12/20

    Research areas

  • liver fibrosis, diagnosis, urine, blood, NAFLD, biomarkers

    Flemish discipline codes

  • Biomarker discovery

ID: 43768803